



Dear Photonics21 Secretariat

We herewith submit the nomination of the following Photonics21 Board of Stakeholder candidate (organization) / representative (person).

**- Letter of Nomination -  
Photonics21 Board of Stakeholders  
Election 2018**

## Photonics21 Board of Stakeholders - Letter of Nomination

*§ 5 BOARD OF STAKEHOLDERS (6) b....A candidate nomination will always contain the name of the candidate organisation together with its proposed BoS Representative, and voting on a candidate implies voting on this combination.*

**1. Full legal name of the affiliation nominated as BoS Member (candidate's organisation):**

Philips Medical Systems Nederland B.V.

**2. Full contact details of the affiliation (street, postal code, country) nominated as BoS Member and invoice address (in case the candidate is elected, the affiliation needs to pay an annual service fee according the Photonics21 Terms of Reference §5 (10)):**

Veenpluis 4-6, 5684 PC Best, the Netherlands

**3. Name of the suggested BoS Representative (the personal candidate)**

Casper Garos

**4. Information about the BoS candidate and the BoS representative**

*Extract Photonics21 Terms of Reference<sup>1</sup>: “§ 5 BOARD OF STAKEHOLDERS; ... (6) Election of BoS Members: “Description of the activities of, and information about the added value and contribution to the BoS by both the nominated BoS member and the BoS Representative”*

**a) Description of the activities and information about the expected contribution and value added the nominated BoS member (candidates organization) will bring to the BoS<sup>2</sup>**

In Europe clearly there is a growing interest and need for breakthrough research and innovation in the healthcare domain, in particular in biophotonic technologies.

Already over many years, Philips has been a key player in Europe regarding public-private partnerships. In FP7 and Horizon 2020 Philips as company has a leading position, which it plans to continue under HorizonEurope. Also in the ECSEL joint-undertaking as well as in EUREKA's ITEA and PENTA clusters, Philips occupies a primary position. Through the extensive collaborative research and innovation efforts, Philips has been able to create a lot of value and jobs in Europe, not only for themselves but also for many partners, including a wide range of SMEs.

Biophotonics is an important new and rapidly growing market, and fortunately over the last years several H2020 ICT calls have helped developing the European medical technology ecosystem. The BoS can definitely benefit from the expertise Philips already has in this area in executing the Photonics21 agenda, especially with regard to the priorities set by WG 3.

---

<sup>1</sup> Photonics21 Terms of reference are available at [https://www.photonics21.org/download/about-us/structure/ETP\\_Photonics21\\_Terms\\_of\\_Reference\\_C3.pdf?m=1513688127&m=1499877714](https://www.photonics21.org/download/about-us/structure/ETP_Photonics21_Terms_of_Reference_C3.pdf?m=1513688127&m=1499877714)

<sup>2</sup> The candidate is aware and accepts that according to the Photonics21 Terms of Reference a service agreement and a service fee invoice is to be signed / paid with the Photonics21 association.

## Photonics21 Board of Stakeholders - Letter of Nomination

- b)** Description of the activities and information about expected contribution and value added the BoS Representative (candidate / person) will bring to the BoS.

From 2007 onwards the candidate is working in the area of public-private partnerships (PPPs) for Philips. Since February 2017 the candidate is Head of Public-Private Partnerships at Philips (i.e. being responsible for PPP for the entire company). In this context, the candidate has very extensive experience enabling new innovations, collaborations and networks. In addition, the candidate oversees a portfolio of more than 100 international PPP projects.

The candidate has been member of the Dutch Point-One innovation program's Management Committee during 2007-2008 and has been member of the FP7's RoboEarth Advisory Committee. Since 2011 the candidate is chair of the COCIR Research & Innovation Focus Group (COCIR is the Brussels based European association for medical technology companies). Members of this Focus Group are amongst others: Philips, Siemens, GE, Agfa, Elekta, Hitachi, Varian and IBA. In addition, since 2017 the candidate is member of the Research and Technology Innovation Working Group of Business Europe and is fulfilling several board positions at national (Dutch) innovation groups or associations.

With the importance of new biophotonic applications, the candidate is expected to help implementing the priorities of the Photonics21 organization, such as the Strategic Multiannual Roadmap 2021-2027. In particular, contributing to the R&I challenges defined in WG3 are automatic. In doing so, it is ensured that leading European institutes and universities are included, as well as key players in the medical technology industry. In short, it would be beneficial to have a representative from Philips in the BoS to assure appropriate attention and focus for biophotonic innovations and to represent the market/industry view. In the end it is essential that novel biophotonic innovations reach the market and, thus, are of benefit the society at large.

### *Final information from the Photonics21 secretariat:*

- *We recommend limiting the BoS nomination letter to 3-4 pages max.*
- *Letters of nominations should be either submitted via the Photonics21 website*

<https://www.photonics21.org/bos-election/index.php>

or via e-mail to [secretariat@photonics21.org](mailto:secretariat@photonics21.org) .

- *It is highly recommended to consult the Photonics21 Terms of Reference before submitting the nomination.*
- *Please note that the deadline for providing BoS nominations to the Photonics21 Secretariat is the **21<sup>st</sup> September 2018.***